title: RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease?
abstract: BACKGROUND
  Jawbone cavitations (JC) are hollow dead spaces in jawbones with dying or dead bone marrow. These areas are defined as fatty degenerative osteonecrosis of the jawbone or neuralgia-inducing cavitational osteonecrosis and may produce facial pain. These afflictions have been linked to the immune system and chronic illnesses. Surgical debridement of JC is reported to lead to an improvement in immunological complaints, such as rheumatic, allergic, and other inflammatory diseases (ID). Little is known about the underlying cause/effect relationship.
  
  
  OBJECTIVE
  JC bone samples were analyzed to assess the expression and quantification of immune modulators that can play a role in the pathogenesis of IDs. The study supports a potential mechanism where JC is a mediating link in IDs.
  
  
  METHODS
  Samples of fatty softened bone taken from JCs were extracted from 31 patients. The specimens were analyzed by bead-based multiplex technology and tested for seven immune messengers.
  
  
  RESULTS
  Regulated upon activation, normal T-cell expressed, and secreted (RANTES) and fibroblast growth factor (FGF)-2 were found at high levels in the JCs tested. Other cytokines could not be detected at excessive levels.
  
  
  CONCLUSIONS
  The study confirms that JC is able to produce inflammatory messengers, primarily RANTES, and, secondarily, FGF-2. Both are implicated in many serious illnesses. The excessive levels of RANTES/FGF-2 in JC patients with amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, and breast cancer are compared to levels published in medical journals. Levels detected in JCs are higher than in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis and multiple sclerosis patients and four-fold higher than in breast cancer tissue.
  
  
  CONCLUSIONS
  This study suggests that JC might serve as a fundamental cause of IDs, through RANTES/FGF-2 production. Thus, JC and implicated immune messengers represent an integrative aspect of IDs and serve as a possible cause. Removing JCs may be a key to reversing IDs. There is a need to raise awareness about JC throughout medicine and dentistry.
authors: Clinic for Integrative Dentistry, Munich, Germany.
authors: Johann
authors: J
authors: Lechner
authors: Volker
authors: V
authors: von Baehr
keywords: CCL5; FGF-2; NICO; RANTES; bead-based Luminex analysis; fibroblast growth factor; osteolytic degenerated jaw bone; systemic signaling pathways
references: Int J Cancer. 2003 Nov 1;107(2):197-201
references: 12949794
references: Neurosci Lett. 2008 Apr 25;435(3):223-8
references: 18353554
references: Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):323-40
references: 12220547
references: Cancer Res. 2002 Feb 15;62(4):1093-102
references: 11861388
references: Oral Surg Oral Med Oral Pathol. 1992 Mar;73(3):307-19; discussion 319-20
references: 1545963
references: Neuroreport. 2003 Oct 6;14(14):1867-9
references: 14534437
references: Clin Cancer Res. 2000 Aug;6(8):3147-52
references: 10955796
references: Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;61(4):263-7
references: 1685819
references: Cancer Res. 1997 Mar 1;57(5):963-9
references: 9041202
references: J Neuroimmunol. 1998 Jan;81(1-2):49-57
references: 9521605
references: Clin Cancer Res. 2005 Nov 15;11(22):8036-41
references: 16299233
references: Clin Chem. 1998 Apr;44(4):705-23
references: 9554481
references: Cancer Cells. 1991 Jun;3(6):239-43
references: 1911037
references: Ann Rheum Dis. 2002 Sep;61(9):834-7
references: 12176812
references: Clin Cancer Res. 1999 May;5(5):1063-71
references: 10353739
references: Int J Obes (Lond). 2009 Jan;33(1):54-66
references: 19050672
references: Bratisl Lek Listy. 2008;109(1):8-9
references: 18447253
references: Curr Hematol Rep. 2003 Sep;2(5):417-22
references: 12932315
references: Ann Oncol. 1999 Jun;10(6):707-13
references: 10442194
references: Gynecol Oncol. 2006 Sep;102(3):542-5
references: 16510173
references: Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1304-10
references: 18420999
references: Glia. 2002 Jul;39(1):19-30
references: 12112372
references: J Egypt Natl Canc Inst. 2005 Mar;17(1):51-5
references: 16353083
references: J Immunol. 2009 Apr 1;182(7):3945-6
references: 19299688
references: Clin Exp Immunol. 1995 Sep;101(3):398-407
references: 7545093
references: Nature. 2007 Oct 4;449(7162):557-63
references: 17914389
references: Mol Hum Reprod. 2000 Mar;6(3):246-51
references: 10694272
references: Jpn J Cancer Res. 1993 Dec;84(12):1300-8
references: 8294220
references: Am J Pathol. 1993 Aug;143(2):401-9
references: 7688183
references: Br J Cancer. 1999 Mar;79(7-8):1025-31
references: 10098731
references: Int J Cancer. 2006 Apr 1;118(7):1750-8
references: 16217764
references: Anticancer Res. 2011 Oct;31(10):3219-27
references: 21965729
references: Clin Cancer Res. 2001 Feb;7(2):285-9
references: 11234881
references: Clin Exp Rheumatol. 2005 May-Jun;23(3):379-84
references: 15971427
references: J Rheumatol. 2003 Apr;30(4):783-91
references: 12672200
references: Cancer Res. 2003 Sep 15;63(18):5754-60
references: 14522896
references: Nat Med. 1997 Oct;3(10):1137-40
references: 9334727
references: Int Immunol. 1999 Apr;11(4):553-9
references: 10323208
references: J Natl Cancer Inst. 1993 Feb 3;85(3):241-2
references: 8423630
references: J Clin Endocrinol Metab. 2008 Aug;93(8):3215-21
references: 18492752
references: Cancer Res. 1988 Apr 15;48(8):2083-8
references: 3349479
references: Eur Cytokine Netw. 2001 Jul-Sep;12(3):445-52
references: 11566625
references: Clin Immunol Immunopathol. 1998 Oct;89(1):44-53
references: 9756723
references: Annu Rev Immunol. 2000;18:217-42
references: 10837058
references: Circulation. 2007 Feb 27;115(8):1029-38
references: 17296858
references: Endocr Relat Cancer. 2004 Dec;11(4):709-24
references: 15613447
references: J Neurol Sci. 2006 Apr 15;243(1-2):21-30
references: 16376944
references: Arthritis Rheum. 2006 Aug;54(8):2585-93
references: 16868981
references: Cancer Lett. 2008 Aug 28;267(2):271-85
references: 18439751
references: J Biol Chem. 1993 Mar 15;268(8):5834-9
references: 7680648
references: Eur J Immunol. 1993 Mar;23(3):761-7
references: 7680615